Abstract
Chimeric antigen receptor (CAR) T-cell therapy is highly effective for treating blood cancers such as B-cell malignancies, however, its effectiveness as an approach to treat solid tumors remains to be further explored. Here, we focused on the development of CAR-T cell therapies targeting tropomyosin-related kinase receptor B (TRKB), a highly expressed protein that is significantly associated with tumor progression, malignancy, and drug resistance in multiple forms of aggressive solid tumors. To achieve this, we screened brain-derived neurotrophic factor (BDNF) and neurotrophin 4 (NTF4) ligand-based CAR-T cells for their efficiency in targeting the TRKB receptor in the context of solid tumors, particularly hepatocellular carcinoma and pancreatic cancer. We demonstrated that TRKB is overexpressed not only in hepatocellular carcinoma and pancreatic carcinoma cell lines but also in cancer stem-like cells (CSCs). Notably, BDNF-CAR T and NTF4-CAR T cells could not only effectively target and kill TRKB-expressing pan-cancer cell lines in a dose-dependent manner but also effectively kill CSCs. We also performed in vivo studies to show that NTF4-CAR T cells have a better potential to inhibit the tumor growth of hepatocellular carcinoma xenografts in mice, compared with BDNF-CAR T cells. Taken together, our findings suggest that CAR-T targeting TRKB may be a promising approach for developing novel therapies to treat solid cancers.
Similar content being viewed by others
Data availability
All data and materials for this study are available from the respective authors upon reasonable request.
Abbreviations
- TRKB:
-
Tropomyosin-related kinase receptor B
- TRK:
-
Tropomyosin-related kinase
- BDNF:
-
Brain-derived neurotrophic factor
- NTF4:
-
Neurotrophin 4
- CSCs:
-
Cancer stem-like cells
- CAR-T:
-
Chimeric antigen receptor T
- NTKR2:
-
Neurotrophic tyrosine kinase receptor 2
- scFv:
-
Single-chain fragment variable
- NTD:
-
Non-transduced T cells
- CRS:
-
Cytokine release syndrome
- ICANS:
-
Cell-associated neurotoxicity syndrome
References
Vargason AM, Anselmo AC, Mitragotri S (2021) The evolution of commercial drug delivery technologies. Nat Biomed Eng 5(9):951–967
Singh AK, McGuirk JP (2020) CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol 21(3):e168–e178
Prasad V (2018) Immunotherapy: tisagenlecleucel—the first approved CAR-T-cell therapy—implications for payers and policy makers. Nat Rev Clin Oncol 15(1):11–12
Lu J, Jiang G (2022) The journey of CAR-T therapy in hematological malignancies. Mol Cancer 21(1):194
Atashzar MR, Baharlou R, Karami J, Abdollahi H, Rezaei R, Pourramezan F, Zoljalali Moghaddam SH (2020) Cancer stem cells: a review from origin to therapeutic implications. J Cell Physiol 235(2):790–803
Kumar D, Kumar S, Gorain M, Tomar D, Patil HS, Radharani NNV, Kumar TVS, Patil TV, Thulasiram HV, Kundu GC (2016) Notch1-MAPK signaling axis regulates CD133(+) cancer stem cell-mediated melanoma growth and angiogenesis. J Invest Dermatol 136(12):2462–2474
Wei W, Hu H, Tan H, Chow LW, Yip AY, Loo WT (2012) Relationship of CD44+CD24−/low breast cancer stem cells and axillary lymph node metastasis. J Trans Med. https://doi.org/10.1186/1479-5876-10-S1-S6
Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, Cherif H, Uddin S, Steinhoff M, Marincola FM et al (2023) CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer 22(1):20
Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15(12):731–747
Wang X, Prager BC, Wu Q, Kim LJY, Gimple RC, Shi Y, Yang K, Morton AR, Zhou W, Zhu Z et al (2018) Reciprocal signaling between glioblastoma stem cells and differentiated tumor cells promotes malignant progression. Cell Stem Cell 22(4):514-528.e515
Jin W, Lee JJ, Kim MS, Son BH, Cho YK, Kim HP (2011) DNA methylation-dependent regulation of TrkA, TrkB, and TrkC genes in human hepatocellular carcinoma. Biochem Biophys Res Commun 406(1):89–95
Johnson MD, Stone B, Thibodeau BJ, Baschnagel AM, Galoforo S, Fortier LE, Ketelsen B, Ahmed S, Kelley Z, Hana A et al (2017) The significance of Trk receptors in pancreatic cancer. Tumour Biol. https://doi.org/10.1177/1010428317692256
Foster WG, Elias R, Faghih M, Dominguez MA, Elit L, Boutross-Tadross O (2009) Immunohistochemical localization of tyrosine receptor kinases A and B in endometriosis-associated ovarian cancer. Histopathology 54(7):907–912
Tanaka K, Mohri Y, Nishioka J, Kobayashi M, Ohi M, Miki C, Tonouchi H, Nobori T, Kusunoki M (2009) Neurotrophic receptor, tropomyosin-related kinase B as an independent prognostic marker in gastric cancer patients. J Surg Oncol 99(5):307–310
Mazouffre C, Geyl S, Perraud A, Blondy S, Jauberteau MO, Mathonnet M, Verdier M (2017) Dual inhibition of BDNF/TrkB and autophagy: a promising therapeutic approach for colorectal cancer. J Cell Mol Med 21(10):2610–2622
Okamura K, Harada T, Wang S, Ijichi K, Furuyama K, Koga T, Okamoto T, Takayama K, Yano T, Nakanishi Y (2012) Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. Lung Cancer 78(1):100–106
Tajbakhsh A, Mokhtari-Zaer A, Rezaee M, Afzaljavan F, Rivandi M, Hassanian SM, Ferns GA, Pasdar A, Avan A (2017) Therapeutic potentials of BDNF/TrkB in breast cancer; current status and perspectives. J Cell Biochem 118(9):2502–2515
Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM (1992) Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Can Res 52(5):1364–1368
Yamashiro DJ, Nakagawara A, Ikegaki N, Liu XG, Brodeur GM (1996) Expression of TrkC in favorable human neuroblastomas. Oncogene 12(1):37–41
Scaruffi P, Cusano R, Dagnino M, Tonini GP (1999) Detection of DNA polymorphisms and point mutations of high-affinity nerve growth factor receptor (TrkA) in human neuroblastoma. Int J Oncol 14(5):935–938
Rydén M, Sehgal R, Dominici C, Schilling FH, Ibáñez CF, Kogner P (1996) Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. Br J Cancer 74(5):773–779
Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17(3):147–167
Branella GM, Spencer HT (2021) Natural receptor- and ligand-based chimeric antigen receptors: strategies using natural ligands and receptors for targeted cell killing. Cells. https://doi.org/10.3390/cells11010021
Ramírez-Chacón A, Betriu-Méndez S, Bartoló-Ibars A, González A, Martí M, Juan M (2022) Corrigendum: ligand-based CAR T-cell—different strategies to drive T-cells in future new treatments. Front Immunol 13:1078003
Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS (2017) Targeting TRK family proteins in cancer. Pharmacol Ther 173:58–66
Au CW, Siu MK, Liao X, Wong ES, Ngan HY, Tam KF, Chan DC, Chan QK, Cheung AN (2009) Tyrosine kinase B receptor and BDNF expression in ovarian cancers: effect on cell migration, angiogenesis and clinical outcome. Cancer Lett 281(2):151–161
Sugiura D, Shimizu K, Maruhashi T, Okazaki IM, Okazaki T (2021) T-cell-intrinsic and -extrinsic regulation of PD-1 function. Int Immunol 33(12):693–698
Sun L, Gao F, Gao Z, Ao L, Li N, Ma S, Jia M, Li N, Lu P, Sun B et al (2021) Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in hepatocellular carcinoma. J Immuno Cancer. https://doi.org/10.1136/jitc-2020-001875
Guo D, Hou X, Zhang H, Sun W, Zhu L, Liang J, Jiang X (2011) More expressions of BDNF and TrkB in multiple hepatocellular carcinoma and anti-BDNF or K252a induced apoptosis, supressed invasion of HepG2 and HCCLM3 cells. J Exp Clin Cancer Res 30(1):97
Sclabas GM, Fujioka S, Schmidt C, Li Z, Frederick WA, Yang W, Yokoi K, Evans DB, Abbruzzese JL, Hess KR et al (2005) Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 11(2 Pt 1):440–449
Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G et al (2022) GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell 40(1):53-69.e59
Nassar D, Blanpain C (2016) Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol 11:47–76
Yin B, Ma ZY, Zhou ZW, Gao WC, Du ZG, Zhao ZH, Li QQ (2015) The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model. Oncogene 34(6):761–770
Kim MS, Lee WS, Jin W (2023) TrkB inhibition of DJ-1 degradation promotes the growth and maintenance of cancer stem cell characteristics in hepatocellular carcinoma. Cell Mol Life Sci 80(10):303
Noh KH, Kim BW, Song KH, Cho H, Lee YH, Kim JH, Chung JY, Kim JH, Hewitt SM, Seong SY et al (2012) Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Investig 122(11):4077–4093
Fan J, Yu Y, Yan L, Yuan Y, Sun B, Yang D, Liu N, Guo J, Zhang J, Zhao X (2023) GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer. J Hematol Oncol 16(1):77
Wei W, Ma H, Yang D, Sun B, Tang J, Zhu Y, Chen X, Huang X, Liu J, Hu Z et al (2023) SECTM1-based CAR-T cells enriched with CD7low/negative subsets exhibit efficacy in CD7-positive malignancies. Blood Adv. https://doi.org/10.1182/bloodadvances.2022008402
Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, Li W, Cai C, Xu J, Zhao X (2019) Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res 7(11):1813–1823
Yang D, Sun B, Dai H, Li W, Shi L, Zhang P, Li S, Zhao X (2019) T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells. J Immunother Cancer 7(1):171
El-Nassan HB, Al-Qadhi MA (2023) Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: a mini review. Eur J Med Chem 258:115618
Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS (2004) Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430(7003):1034–1039
Zhang S, Guo D, Luo W, Zhang Q, Zhang Y, Li C, Lu Y, Cui Z, Qiu X (2010) TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells. BMC Cancer 10:43
Huang YT, Lai PC, Wu CC, Cheng CC, Chiu TH (2010) TrkB antibody elicits cytotoxicity and suppresses migration/invasion of transitional cell carcinoma cells. Int J Oncol 37(4):943–949
Kawamura K, Kawamura N, Okamoto N, Manabe M (2013) Suppression of choriocarcinoma invasion and metastasis following blockade of BDNF/TrkB signaling. Cancer Med 2(6):849–861
Zou J, Zhang Z, Xu F, Cui S, Qi C, Luo J, Wang Z, Lu X, Tu Z, Ren X et al (2019) GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models. J Drug Target 27(4):442–450
Li Q, Han J, Yang Y, Chen Y (2022) PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol 13:1070961
Vander Mause ER, Atanackovic D, Lim CS, Luetkens T (2022) Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity. Trends Biotechnol 40(7):875–890
Dobrowsky RT, Werner MH, Castellino AM, Chao MV, Hannun YA (1994) Activation of the sphingomyelin cycle through the low-affinity neurotrophin receptor. Science 265(5178):1596–1599
Cazorla M, Arrang JM, Prémont J (2011) Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor. Br J Pharmacol 162(4):947–960
Yu S, Yi M, Qin S, Wu K (2019) Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer 18(1):125
Qiang L, Yang Y, Ma YJ, Chen FH, Zhang LB, Liu W, Qi Q, Lu N, Tao L, Wang XT et al (2009) Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 279(1):13–21
Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH, Yao XH, Gao L, Wang JM, Bian XW (2008) Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett 265(1):124–134
Li S, Dai Z, Yang D, Li W, Dai H, Sun B, Liu X, Xie X, Xu R, Zhao X (2019) Targeting β2 subunit of Na(+)/K(+)-ATPase induces glioblastoma cell apoptosis through elevation of intracellular Ca(2). Am J Cancer Res 9(6):1293–1308
Acknowledgements
We gratefully acknowledge for the technical assistance of Core Facility of West China Hospital (Li Chai, Yi Li and Xing Xu), Histology and Imaging Platform, Core Facility of West China Hospital (Yaping Wu). Manuscript editor Julian Heng (Remotely Consulting, Australia) provided professional English-language editing of this article (Manuscript Certificate No. 0Vb8Nn5I).
Funding
This work was supported by the National Natural Science Foundation of China (Grant No. 82103107 to B Sun), National Natural Science Foundation of China (Grant No. 82172701 to X Zhao), and 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Grant No. ZYYC20002 to X Zhao).
Author information
Authors and Affiliations
Contributions
DL and JT have contributed equally to this work. All authors contributed to the conception and design of this study. The experiments were carried out by DL and JT. JT, DL, BS, and DY wrote the original article. SH, HM, YY, and WW analyzed the data. HC and XZ critically revised the article. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflicts of interest in this work.
Ethical approval
Animal experiments in this study were approved by the Animal Ethics Committee of West China Hospital, Sichuan University (ID: 20211492A).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Liang, D., Tang, J., Sun, B. et al. Novel CAR-T cells targeting TRKB for the treatment of solid cancer. Apoptosis (2024). https://doi.org/10.1007/s10495-024-01936-7
Accepted:
Published:
DOI: https://doi.org/10.1007/s10495-024-01936-7